COX‐3—a virtual pain target in humans?
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, further genomic and kinetic studies showed that a full-length, catalytically active form of COX-3 does not exist in humans35,36”
Citations
Cites
Chandrasekharan, N. V., Dai, H., Roos, K. L. T., Evanson, N. K., Tomsik, J., Elton, T. S., & Simmons, D. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162468699 · Cited by 1,989 · cited 4×
“A long-sought molecule (1) was recently identified as acting independent of COX-1/-2 (2).”
BackgroundInfluentialMechanism of Action of Acetaminophen: Is There a Cyclooxygenase 3?
Botting, R. M. (2000) · Clinical Infectious Diseases · doi:10.1086/317520 · Cited by 350
Cyclooxygenase-3 (COX-3): Filling in the gaps toward a COX continuum?
Warner, T. D., & Mitchell, J. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.222543099 · Cited by 302
Cyclooxygenase 1(COX1) polymorphisms in African-American and caucasian populations
Ulrich, C. M., Bigler, J., Sibert, J. G., Greene, E. A., Sparks, R., Carlson, C. S., & Potter, J. D. (2002) · Human Mutation · doi:10.1002/humu.9080 · Cited by 83 · cited 1×
“COX-1 polymorphisms or sequencing errors concerning the nucleotides of intron 1 are implausible since recent screening of the human COX-1 gene, including the complete intron 1 region, revealed no polymorphisms or deletions in intron 1 (7).”
BackgroundBazan, N. G., & Flower, R. (2002) · Nature · doi:10.1038/420135a · Cited by 42
Homing in on COX-3—the elusive target of paracetamol
Senior, K. (2002) · The Lancet Neurology · doi:10.1016/s1474-4422(02)00207-7 · Cited by 8
Smith, A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd951 · Cited by 5
Cited by
Graham, G. G., Davies, M. J., Day, R. O., Mohamudally, A., & Scott, K. F. (2013) · Inflammopharmacology · doi:10.1007/s10787-013-0172-x · Cited by 671
Mechanism of Action of Paracetamol
Graham, G. G., & Scott, K. F. (2005) · American Journal of Therapeutics · doi:10.1097/00045391-200501000-00008 · Cited by 648
“Furthermore, recent DNA analysis makes it unlikely that a catalytically active COX-3 could occur in human tissues.(47,48)”
BackgroundAcetaminophen (paracetamol) is a selective cyclooxygenase‐2 inhibitor in man
Hinz, B., Cheremina, O., & Brune, K. (2008) · The FASEB Journal · doi:10.1096/fj.07-8506com · Cited by 478
“In particular, the existence of a functional human COX-3 has been questioned, given that retention of intron 1 in human COX-3 leads to a shift in the reading frame, a premature termination, and a truncated, COX-inactive protein (10, 11).”
BackgroundArachidonic Acid Metabolism and Kidney Inflammation
Wang, T., Fu, X., Chen, Q., Patra, J. K., Wang, D., Wang, Z., & Gai, Z. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153683 · Cited by 430
Burian, M., & Geisslinger, G. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.02.004 · Cited by 259
“However, on the basis of nucleotide sequence data obtained in humans, the existence of COX-3 has been called to question by at least two independent research groups (Dinchuk et al., 2003; Schwab et al., 2003).”
BackgroundParacetamol (acetaminophen): A familiar drug with an unexplained mechanism of action
Ayoub, S. S. (2021) · Temperature · doi:10.1080/23328940.2021.1886392 · Cited by 223
“[41] Schwab JM, Beiter T, Linder JU, et al.”
BackgroundCyclooxygenase-2 and its role in ovulation: a 2004 account
Sirois, J., Sayasith, K., Brown, K. A., Stock, A. E., Bouchard, N., & Doré, M. (2004) · Human Reproduction Update · doi:10.1093/humupd/dmh032 · Cited by 212
“…2003; Shaftel et al., 2003), but the expression of a functional COX-3 in humans is still debated since intron 1 in this species is 94 nucleotides long, which creates a frameshift that results in a protein sequence not related to COX-1 (Dinchuk et al., 2003; Schwab et al., 2003b; Simmons, 2003).”
BackgroundMultimodal Analgesia Techniques and Postoperative Rehabilitation
Joshi, G. P. (2005) · Anesthesiology Clinics of North America · doi:10.1016/j.atc.2004.11.010 · Cited by 207
Paracetamol – An old drug with new mechanisms of action
Przybyła, G. W., Szychowski, K. A., & Gmiński, J. (2021) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13392 · Cited by 190
The role of phytochemicals in inhibition of cancer and inflammation: New directions and perspectives
Issa, A. Y., Volate, S. R., & Wargovich, M. J. (2006) · Journal of Food Composition and Analysis · doi:10.1016/j.jfca.2006.02.009 · Cited by 170
Hinz, B., Cheremina, O., Bachmakov, J., Renner, B., Zolk, O., Fromm, M. F., & Brune, K. (2007) · The FASEB Journal · doi:10.1096/fj.06-8061com · Cited by 149
“In addition to these concerns, the existence of a functional human COX-3 has been questioned, given that retention of intron 1 in human COX-3 leads to a shift in the reading frame, premature termination, and a truncated, COXinactive protein (27, 28).”
BackgroundEffects of prostaglandins and COX-inhibiting drugs on skeletal muscle adaptations to exercise
Trappe, T. A., & Liu, S. Z. (2013) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00061.2013 · Cited by 98
“Additionally, there are two well-known isoforms of COX—COX-1 and COX-2 (44, 105, 107, 141)—and a possible third isoform (an intron-retaining variant of COX-1, referred to as COX-1b or COX-3) may exist in some tissues (22, 86, 101, 138).”
Cyclooxygenase-3: axiom, dogma, anomaly, enigma or splice error?--Not as easy as 1, 2, 3.
Davies, N. M., Good, R. L., Roupe, K., & Yáñez, J. A. (2004) · PubMed · Cited by 128
The Role of Cyclooxygenase in Gastric Mucosal Protection
Gudis, K., & Sakamoto, C. (2005) · Digestive Diseases and Sciences · doi:10.1007/s10620-005-2802-7 · Cited by 94
Prostacyclin signaling in the kidney: implications for health and disease
Nasrallah, R., & Hébert, R. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00454.2004 · Cited by 94
“It was also detected in human cerebral cortex and heart; however, insertion of intron 1 caused a frame shift, possibly resulting in a nonfunctional protein in humans (110).”
BackgroundUpdate on cyclooxygenase inhibitors: has a third COX isoform entered the fray?
Hersh, E. V., Lally, E. T., & Moore, P. A. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x56367 · Cited by 102
Cloning and Characterization of Cyclooxygenase-1b (Putative Cyclooxygenase-3) in Rat
Snipes, J. A., Kis, B., Shelness, G. S., Hewett, J. A., & Busija, D. W. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.079533 · Cited by 82
“…in these species also encodes an acetaminophen-sensitive cyclooxy- genase as in canines, because in these species the retention of the entire intron-1, which is 98 bp in rat and mouse and 94 bp in human, would shift the original reading frame of COX-1 (Dinchuk et al., 2003; Schwab et al., 2003).”
BackgroundMallet, C., Desmeules, J., Pegahi, R., & Eschalier, A. (2023) · Journal of Pain Research · doi:10.2147/jpr.s393809 · Cited by 83
Qin, N., Zhang, S.-P., Reitz, T. L., Mei, J. M., & Flores, C. M. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.090944 · Cited by 77
“However, the existence of an orthologous splicing variant in human tissue has been questioned because, based on a search of the human genomic DNA database, the complete retention of intron 1 of human COX-1 would result in a frame shift that would be predicted to yield a prematurely terminated and COX-inactive protein…”
BackgroundThe Molecular Toxicology of Acetaminophen
Josephy, P. D. (2005) · Drug Metabolism Reviews · doi:10.1080/03602530500205200 · Cited by 80
“However, further molecular cloning studies (Dinchuk et al., 2003) failed to confirmed the existence of COX-3 in humans, and the possible significance of COX-1 splicing variants remains unclear (Berenbaum, 2004; Schwab et al., 2003).”
BackgroundNunno, L. D., Vitale, P., Scilimati, A., Tacconelli, S., & Patrignani, P. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm040782x · Cited by 73
Inoue, T., Anai, S., Onishi, S., Miyake, M., Tanaka, N., Hirayama, A., Fujimoto, K., & Hirao, Y. (2013) · BMC Urology · doi:10.1186/1471-2490-13-1 · Cited by 68
“COX-3 and one of the PCOX-1 proteins (PCOX-1a) are made from the COX-1 gene but retain intron 1 in their mRNAs [2,3].”
BackgroundStrokin, M., Sergeeva, M. G., & Reiser, G. (2004) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2004.07.002 · Cited by 74
Weinheimer, E. M., Jemiolo, B., Carroll, C. C., Harber, M. P., Haus, J. M., Burd, N. A., LeMoine, J. K., Trappe, S. W., & Trappe, T. A. (2007) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00718.2006 · Cited by 60
“The retention of intron 1 results in the addition of 94 base pairs (7), and it has been argued that this would result in a reading frame shift yielding a prematurely terminated COX-inactive protein (12, 30).”
BackgroundPain and osteoarthritis: new drugs and mechanisms
Hinz, B., & Brune, K. (2004) · Current Opinion in Rheumatology · doi:10.1097/01.hco.0000136130.95746.14 · Cited by 59
The Cycloxygenase 2 (COX-2) Story: It's Time to Explain, Not Inflame
Salinas, G., Rangasetty, U. C., Uretsky, B. F., & Birnbaum, Y. (2007) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248407301172 · Cited by 53
“This enzyme is especially sensitive to acetaminophen and related compounds and may mediate fever,(18) but its role in human pathophysiology is still unclear.(19) Experimental models of arthritis provided the first information regarding expression of COX-2 in acute and chronic inflammation.”
BackgroundProstaglandins in the kidney: developments since Y2K
Nasrallah, R., Clark, J., & Hébert, R. (2007) · Clinical Science · doi:10.1042/cs20070089 · Cited by 57
Hinz, B., & Brune, K. (2007) · Springer eBooks · doi:10.1007/978-3-540-33823-9_3 · Cited by 50
The use of cyclooxygenase-2 inhibitors for improvement of efficacy of radiotherapy in cancers
Salehifar, E., & Hosseinimehr, S. J. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.02.019 · Cited by 53
Role of Cyclooxygenase-2 Inhibitors in Postoperative Pain Management
Gajraj, N. M., & Joshi, G. P. (2005) · Anesthesiology Clinics of North America · doi:10.1016/j.atc.2004.11.011 · Cited by 39
Berenbaum, F. (2004) · Joint Bone Spine · doi:10.1016/j.jbspin.2004.02.003 · Cited by 36
Distal degeneration of sensory and autonomic cutaneous nerve fibres in systemic sclerosis
Provitera, V., Nolano, M., Pappone, N., di Girolamo, C., Stancanelli, A., Lullo, F., Crisci, C., & Santoro, L. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.038935 · Cited by 26
Nurmi, J. T., Puolakkainen, P. A., & Rautonen, N. (2005) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2005.07.004 · Cited by 22
Inactivation of Ovine Cyclooxygenase-1 by Bromoaspirin and Aspirin: A Quantum Chemistry Description
Barroso-Neto, I. L., Marques, J. P. C., da COSTA, R. F., Caetano, E. W. S., Cavada, B. S., Gottfried, C., & Freire, V. N. (2012) · The Journal of Physical Chemistry B · doi:10.1021/jp206397z · Cited by 21
Ayoub, S. S., Pryce, G., Seed, M. P., Bolton, C., Flower, R. J., & Baker, D. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.038638 · Cited by 20
Ayoub, S. S., & Flower, R. J. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172609 · Cited by 19
Gao, I. K., Haas-Wöhrle, A., Mueller, K. G., Lorenz, H.-M., & Fiehn, C. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.035444 · Cited by 21
Aarntzen, E. H. J. G., van Riel, P. L. C. M., & Barrera, P. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.042945 · Cited by 17
Wu, B., Zeng, L., Lin, Y., Wen, Z.-F., Chen, G., Iwakiri, R., & Fujimoto, K. (2009) · Cell Research · doi:10.1038/cr.2009.97 · Cited by 15
Mavragani, C., Batziou, K., Aroni, K., Pikazis, D., & Manoussakis, M. N. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.032433 · Cited by 14
Lorenz, H.-M., Grunke, M., Wendler, J., Heinzel, P. A., & Kalden, J. R. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.035329 · Cited by 15
Müller‐Decker, K. (2004) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1046/j.1439-0353.2004.04042.x · Cited by 14
Acetaminophen may act through β endorphin
Sprott, H., Shen, H., Gay, S., & Aeschlimann, A. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.033712 · Cited by 14
Reinauer, C., Censarek, P., Kaber, G., Weber, A.-A., Steger, G., Klamp, T., & Schrör, K. (2013) · bchm · doi:10.1515/hsz-2012-0309 · Cited by 7
Le paracétamol : un ancêtre plein d’avenir
Mallet, C., Barrière, D. A., & Eschalier, A. (2012) · Therapies · doi:10.2515/therapie/2012039 · Cited by 10
Stern, S. S., & Ponticello, M. N. (2008) · Clinics in Podiatric Medicine and Surgery · doi:10.1016/j.cpm.2008.02.013 · Cited by 4
Paracetamol (N-acetyl-p-aminophenol, APAP) Threats: Therapeutic Clock
Prasad, T., Singh, S., Kumar, P., Rathi, R., Kumar, N., Anuj, Sharma, S., Nisha, N., Dhanajaybharati, Abhishek, A., et al. (2023) · International Journal of Pharma Professional’s Research (IJPPR) · doi:10.48165/ijppronline.2023.14203 · Cited by 4
Zakharova, I. N., Berezhnaya, I. V., Pupykina, V. V., Gostyukhina, A. D., & Dubovets, N. F. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2023-367 · Cited by 4
Kazakos, G. M., Savvas, I., & Raptopoulos, D. (2017) · Journal of the Hellenic Veterinary Medical Society · doi:10.12681/jhvms.14990 · Cited by 3
Schmerztherapie mit antipyretischen Analgetika
Hinz, B., & Brune, K. (2006) · Der Orthopäde · doi:10.1007/s00132-006-1024-9 · Cited by 3
Introduction: Discovery of Cyclooxygenases and Historical Perspective
Radi, Z. A. (2012) · Wiley eBooks · doi:10.1002/9781118351918.ch · Cited by 2
Nonsteroidal Anti-Inflammatory Drugs
Flower, R. J. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9781139195737.020 · Cited by 2
Berenbaum, F. (2004) · Revue du Rhumatisme · doi:10.1016/j.rhum.2004.02.004 · Cited by 1
La innovación farmacéutica. Comentarios sobre tres noticias
Avendaño, C. (2005) · Anales de la Real Academia Nacional de Farmacia
Some Challenges of Postoperative Pain Treatment
Puolakka, P. A. (2011) · Tampere University Institutional Repository (Tampere University) · Cited by 5
skeletal muscle adaptations to exercise Effects of prostaglandins and COX-inhibiting drugs on
Trappe, T. A., Liu, S. Z., Markworth, J. F., Vella, L. D., Figueiredo, V. C., Cameron‐Smith, D., Broderick, T. L., Carroll, C. C., Martineau, K., Arthur, K. A., et al. (2015)
health and disease Prostacyclin signaling in the kidney: implications for
Nasrallah, R., & Hébert, R. (2016)
Development of Cyclooxygenases in the Treatment of Pain, Fever and Inflammation.
Asif, M. (2014) · Research and reviews : journal of pharmaceutics and nanotechnology · Cited by 1
Medical Management of Renal and Ureteral Stones
Lukaszyk, D., & Knoll, T. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00093-1
Metadata
- Authors
- Schwab, J. M., Beiter, T., Linder, J. U., Laufer, S., Schulz, J. E., Meyermann, R., & Schluesener, H. J.
- Affiliations
- University of Tübingen (DE)
- Institute of Brain Research, Medical School D-72076 Tuebingen Germany
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2003-12
- Volume
- 17
- Issue
- 15
- Pages
- 2174-2175
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2098921614
- Cited by
- 59
- References
- 7
- Citations by year
- 2023: 3 · 2021: 2 · 2020: 1 · 2019: 2 · 2017: 1 · 2016: 2 · 2015: 1 · 2014: 1 · 2013: 4 · 2012: 3
- FWCI
- 6.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The FASEB Journal (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
- Keywords
- COX-3, pain, analgesia, cyclooxygenase-2, cyclooxygenase-1
- MeSH terms
- Amino Acid Sequence, Base Sequence, Humans, Introns, Isoenzymes, Membrane Proteins, Molecular Sequence Data, Prostaglandin-Endoperoxide Synthases, Frameshift Mutation, Drug Delivery Systems, Cyclooxygenase Inhibitors, Cyclooxygenase 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.